NASDAQ: ATHAAthira Pharma Inc Stock
$1.44-0.09 (-5.88%)
Updated Nov 28, 2023
ATHA Price
$1.44
Fair Value Price
N/A
Market Cap
$54.80M
52 Week Low
$1.33
52 Week High
$4.41
P/E
-0.45x
P/B
0.35x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$120.52M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.19
Operating Cash Flow
-$90M
Beta
1.31
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ATHA Overview
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company developing small molecules to restore neuronal health and stop neurodegeneration brought on by Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease.Known as M3 Biotechnology, Inc. until 2019/04, the company was incorporated in 2011 and is headquartered in Bothell, WA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ATHA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATHA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ATHA is good value based on its book value relative to its share price (0.35x), compared to the US Biotechnology industry average (5.31x)
P/B vs Industry Valuation
ATHA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ATHA due diligence checks available for Premium users.
Be the first to know about important ATHA news, forecast changes, insider trades & much more!
ATHA News
Valuation
ATHA fair value
Fair Value of ATHA stock based on Discounted Cash Flow (DCF)
Price
$1.44
Fair Value
$4.35
Undervalued by
66.92%
ATHA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ATHA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.45x
Industry
12.55x
Market
32.56x
ATHA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.35x
Industry
5.31x
ATHA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATHA's financial health
Profit margin
Revenue
$0.0
Net Income
-$33.0M
Profit Margin
0%
ATHA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$184.7M
Liabilities
$29.9M
Debt to equity
0.19
ATHA's short-term assets ($178.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATHA's short-term assets ($178.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATHA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.0M
Investing
$20.7M
Financing
$0.0
ATHA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATHA vs Biotech Stocks
Athira Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.